文献速递淋巴瘤

超深度测序液体活检与PET/CT对滤泡性淋巴瘤患者的真实世界疾病监测

Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT.
PubMed 文献 · Leukemia · 2023-01-03

本研究用靶向NGS panel筛选84例滤泡性淋巴瘤患者的可追踪突变,并在54例接受治疗患者的151份随访液体活检样本中以灵敏度2·10⁻⁴的超深度测序(LiqBio-MRD)追踪。一线治疗中LiqBio-MRD阳性与更高的进展风险相关(中期HR 11.0,95%CI 2.10-57.7,p=0.005;治疗结束HR 19.1,95%CI 4.10-89.4,p<0.001)。LiqBio-MRD联合PET/CT识别2年内进展患者的灵敏度88%、特异度100%。

要点

  • 淋巴结样本可追踪突变检出率95%,液体活检基线样本80%。
  • 一线治疗中期LiqBio-MRD阳性者进展风险HR 11.0(95%CI 2.10-57.7,p=0.005)。
  • 治疗结束时LiqBio-MRD阳性者进展风险HR 19.1(95%CI 4.10-89.4,p<0.001)。

核心结论

  • LiqBio-MRD是稳健、非侵入的方法,可补充代谢影像,识别治疗期间高失败风险的滤泡性淋巴瘤患者,应考虑用于未来反应引导的临床试验。

研究设计与样本

  • 本研究筛选84例滤泡性淋巴瘤患者,使用靶向下一代测序panel寻找适合作为液体活检MRD生物标志物的体细胞突变。
  • 对54例接受治疗患者的151份随访液体活检样本,采用灵敏度2·10⁻⁴的超深度测序(LiqBio-MRD)追踪突变。

主要发现

  • 淋巴结样本中可追踪突变检出率为95%,液体活检基线样本为80%。
  • 一线治疗中期LiqBio-MRD阳性与进展风险升高相关(HR 11.0,95%CI 2.10-57.7,p=0.005)。
  • 治疗结束时LiqBio-MRD阳性与进展风险升高相关(HR 19.1,95%CI 4.10-89.4,p<0.001)。
  • PET/CT Deauville评分显示,中期中位PFS为19个月 vs NR(p<0.001),治疗结束为13个月 vs NR(p<0.001)。
  • LiqBio-MRD联合PET/CT识别2年内进展患者的灵敏度为88%,特异度为100%。

关键数值与推荐

  • LiqBio-MRD检测灵敏度为2·10⁻⁴。
  • 中期LiqBio-MRD阳性进展风险HR 11.0(95%CI 2.10-57.7,p=0.005)。
  • 治疗结束LiqBio-MRD阳性进展风险HR 19.1(95%CI 4.10-89.4,p<0.001)。
  • LiqBio-MRD联合PET/CT识别2年内进展:灵敏度88%,特异度100%。

临床怎么用

  • 作者认为LiqBio-MRD是稳健、非侵入的方法,可补充代谢影像,识别治疗期间高失败风险的滤泡性淋巴瘤患者。
  • 作者认为LiqBio-MRD应考虑用于未来反应引导的临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the present study, we screened 84 Follicular Lymphoma patients for somatic mutations suitable as liquid biopsy MRD biomarkers using a targeted next-generation sequencing (NGS) panel. We found trackable mutations in 95% of the lymph node samples and 80% of the liquid biopsy baseline samples. Then, we used an ultra-deep sequencing approach with 2 · 10-4 sensitivity (LiqBio-MRD) to track those mutations on 151 follow-up liquid biopsy samples from 54 treated patients. Positive LiqBio-MRD at first-line therapy correlated with a higher risk of progression both at the interim evaluation (HRINT 11.0, 95% CI 2.10-57.7, p = 0.005) and at the end of treatment (HREOT, HR 19.1, 95% CI 4.10-89.4, p < 0.001). Similar results were observed by PET/CT Deauville score, with a median PFS of 19 months vs. NR (p < 0.001) at the interim and 13 months vs. NR (p < 0.001) at EOT. LiqBio-MRD and PET/CT combined identified the patients that progressed in less than two years with 88% sensitivity and 100% specificity. Our results demonstrate that LiqBio-MRD is a robust and non-invasive approach, complementary to metabolic imaging, for identifying FL patients at high risk of failure during the treatment and should be considered in future response-adapted clinical trials.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jiménez-Ubieto A, Poza M, Martin-Muñoz A, et al. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT. Leukemia. 2023. PMID: 36596983. doi:10.1038/s41375-022-01803-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。